- Home
- ALX vs CLDX Comparison
ALX vs CLDX Comparison
Compare ALX & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- CLDX
- Stock Information
- Founded
- ALX 1928
- CLDX N/A
- Country
- ALX United States
- CLDX United States
- Employees
- ALX N/A
- CLDX N/A
- Industry
- ALX Real Estate Investment Trusts
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ALX Real Estate
- CLDX Health Care
- Exchange
- ALX Nasdaq
- CLDX Nasdaq
- Market Cap
- ALX 1.2B
- CLDX 1.3B
- IPO Year
- ALX N/A
- CLDX 2008
- Fundamental
- Price
- ALX $228.01
- CLDX $22.00
- Analyst Decision
- ALX Sell
- CLDX Buy
- Analyst Count
- ALX 1
- CLDX 9
- Target Price
- ALX $125.00
- CLDX $50.00
- AVG Volume (30 Days)
- ALX 77.9K
- CLDX 1.2M
- Earning Date
- ALX 08-04-2025
- CLDX 08-07-2025
- Dividend Yield
- ALX 7.74%
- CLDX N/A
- EPS Growth
- ALX N/A
- CLDX N/A
- EPS
- ALX 7.72
- CLDX N/A
- Revenue
- ALX $219,892,000.00
- CLDX $7,559,000.00
- Revenue This Year
- ALX N/A
- CLDX N/A
- Revenue Next Year
- ALX N/A
- CLDX N/A
- P/E Ratio
- ALX $30.12
- CLDX N/A
- Revenue Growth
- ALX N/A
- CLDX 24.49
- 52 Week Low
- ALX $184.76
- CLDX $14.40
- 52 Week High
- ALX $251.63
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- ALX 61.13
- CLDX 58.43
- Support Level
- ALX $222.50
- CLDX $19.52
- Resistance Level
- ALX $231.23
- CLDX $22.47
- Average True Range (ATR)
- ALX 5.35
- CLDX 1.44
- MACD
- ALX 0.07
- CLDX 0.09
- Stochastic Oscillator
- ALX 91.91
- CLDX 52.66
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.